Ocular, Vascular, and Genetic Findings in AMD Patients

NCT ID: NCT06015633

Last Updated: 2025-02-21

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Total Enrollment: 50 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-10-15
• Study Completion Date: 2025-05-31

Brief Summary

Observation of findings associated with AMD

Detailed Description

Explorational observation of ocular, vascular, and genetic findings in patients diagnosed with AMD

Conditions

Age-Related Macular Degeneration

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: OTHER

Study Groups

Exudative AMD

Subjects that have at least one eye with a history of, or active, exudative age related macular degeneration

No intervention

Intervention Type: OTHER

Observational only

Non-exudative AMD

Subjects that have at least one eye with late stage non-exudative age-related macular degeneration (presence of geographic atrophy)

No intervention

Intervention Type: OTHER

Observational only

Interventions

No intervention

Observational only

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. At least 55 years of age at the time of consent

2. Able to understand and provide written informed consent

3. Sufficiently clear ocular media, adequate pupillary dilation, and adequate fixation to permit quality fundus imaging

4. Able to cooperate with ophthalmic visual function testing and anatomic assessments

5. Diagnosed with late-stage AMD in at least one eye. (if both eyes of an eligible subject meet inclusion criterion, the more advanced eye will receive primary eye assignment)

6. Willing to have protocol specified genetic testing

7. Willing to have head coil MRI/A (with contrast if deemed necessary)

Exclusion Criteria

Ocular

1. History of any retinal disease other than AMD in either eye

2. Spherical equivalent refractive error demonstrating >6 diopters of myopia or an axial length >26 mm in the study eye

3. History of vitrectomy in the study eye

4. Any intraocular surgery (including lens replacement surgery) in the study eye, within 90 days of enrollment

5. History of endophthalmitis

6. Trabeculectomy or aqueous shunt or valve in the study eye

7. Aphakia or absence of the posterior capsule in the study eye (Note: Previous violation of the posterior capsule is also excluded unless it occurred as a result of yttrium aluminum garnet [YAG] laser posterior capsulotomy in association with prior posterior chamber intraocular lens implantation and at least 90 days prior to enrollment)

8. Presence of advanced guttae or visually significant keratopathy that would cause scattering of light or alter visual function in the study eye

9. History of idiopathic or autoimmune-associated uveitis in either eye

10. Active inflammation or infection, including conjunctivitis, keratitis, or scleritis in either eye

11. GA secondary to a condition other than AMD (e.g., Stargardt's disease, cone rod dystrophy, or toxic maculopathies such as Plaquenil maculopathy) in either eye

Non-Ocular

12. Use of any investigational product or investigational medical device (i.e., not approved by FDA for the specific use) within 90 days prior to screening or anticipated use during the study

13. Women of childbearing potential who are pregnant or unwilling to use effective contraception for the duration of the study

14. Acute or serious illness, in the opinion of the site investigator

15. History of kidney failure or gadolinium toxicity

• Minimum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

OcuDyne, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Luana Wilbur, BS

Role: STUDY_DIRECTOR

OcuDyne VP, Clinical and Regulatory Affairs

Locations

Tel Aviv Sourasky Medical Center

Tel Aviv, , Israel

Countries

Israel

Other Identifiers

OC-2301TV

Identifier Type: -

Identifier Source: org_study_id